Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations (such as opioid overdose and anaphylactic shock) based on its microsphere technology.Nasus's portfolio comprises a number of programs including intranasal naloxone, intranasal epinephrine, and a number of preclinical proof-of-concept programs.